Development of a TGFβ—IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy

Therapy employing T cells modified with chimeric antigen receptors (CARs) is effective in hematological malignancies but not yet in solid cancers. CAR T cell activity in solid tumors is limited by immunosuppressive factors, including transforming growth factor β (TGFβ). Here, we describe the develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Beck, Carole, Casey, Nicholas Paul, Persiconi, Irene, Moharrami, Neda Nejati, Sike, Adam, Jin, Yixin, Kyte, Jon Amund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953633/
https://www.ncbi.nlm.nih.gov/pubmed/36830995
http://dx.doi.org/10.3390/biomedicines11020459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953633/
https://www.ncbi.nlm.nih.gov/pubmed/36830995
http://dx.doi.org/10.3390/biomedicines11020459

Ejemplares similares